A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2011-06-30
Target enrollment:
Participant gender:
Summary
The Belinostat-Erlotinib trial is designed as an open, non randomized phase I / II trial to
assess the efficacy and safety of Belinostat in combination with Erlotinib in patients with
non-small cell lung cancer who are eligible for treatment with erlotinib.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Herlev Hospital
Collaborators:
Bispebjerg Hospital Copenhagen University Hospital at Herlev Onxeo Roche Pharma AG